MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

Search

Ipsen SA.

Open

BrancheFinanzen

98 -0.51

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

96.1

Max

98.5

Schlüsselkennzahlen

By Trading Economics

Einkommen

-118M

114M

Verkäufe

71M

1.8B

KGV

Branchendurchschnitt

21.241

20.525

Dividendenrendite

1.54

Gewinnspanne

6.249

Angestellte

5,358

EBITDA

228M

710M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+21.76% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.54%

4.36%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

7.5B

Vorheriger Eröffnungskurs

98.51

Vorheriger Schlusskurs

98

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Ipsen SA. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Dez. 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer-Vergleich

Kursveränderung

Ipsen SA. Prognose

Kursziel

By TipRanks

21.76% Vorteil

12-Monats-Prognose

Durchschnitt 119.75 EUR  21.76%

Hoch 145 EUR

Tief 100 EUR

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ipsen SA. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

8 ratings

3

Buy

4

Halten

1

Sell

Technischer Score

By Trading Central

94.4 / 99.15Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.